Vertex Pharmaceuticals (NASDAQ:VRTX) Downgraded by StockNews.com : vimarsana.com

StockNews.com cut shares of Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) from a strong-buy rating to a buy rating in a research report sent to investors on Saturday morning. A number of other equities analysts have also recently weighed in on the stock. Truist Financial upped their price objective on shares of Vertex Pharmaceuticals from $456.00 […]

Related Keywords

Sherbrooke , Quebec , Canada , Zurcher Kantonalbank Zurich Cantonalbank , Ourania Tatsis , News Ratings For Vertex Pharmaceuticals Daily , Vertex Pharmaceuticals Price Performance , Jpmorgan Chase Co , Vertex Pharmaceuticals , Wolfe Research , Morgan Stanley , Sherbrooke Park Advisers , Nasdaq , Royal Bank , Securities Exchange Commission , Vertex Pharmaceuticals Incorporated , Institutional Trading Of Vertex Pharmaceuticals , Vertex Pharmaceuticals Company Profile , Barclays , Analyst Recommendations For Vertex Pharmaceuticals , Free Report , Get Free Report , Exchange Commission , Chairman Jeffrey , Park Advisers , Kantonalbank Zurich Cantonalbank , Pharmaceuticals Incorporated , Vertex Pharmaceuticals Daily , Nasdaq Vrtx , Vrtx , Medical , 92532f10 , Downgrade , Stocknews Com ,